SIV DNA VACCINES AND MUCOSAL IMMUNITY

SIV DNA 疫苗和粘膜免疫

• 批准号: 8357900
• 负责人: ANNA ALDOVINI
• 金额: $ 6.84万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357900
• 关键词: AIDS Vaccines; AIDS vaccine development; DNA; DNA Vaccines; Development; Disadvantaged; Funding; Grant; HIV; HIV Infections; Immunologic Deficiency Syndromes; Infection; Mucosal Immunity; National Center for Research Resources; New England; Primates; Principal Investigator; Recombinants; Research; Research Infrastructure; Resources; Route; SIV; Source; United States National Institutes of Health; Vaccination; Vaccines; Vaccinia; Vaccinium; base; cost; transmission process; vaccine candidate

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. SIV DNA vaccines and mucosal immunity More than 80% of global transmission of HIV infection occurs via mucosal routes. The ability of vaccines to induce mucosal immunity may be required for protection against HIV infection and the immunodeficiency syndrome that emerges after infection. Various AIDS vaccine candidates are currently under development, each with potential advantages and disadvantages. DNA vaccines have features that make them attractive vaccine candidates for HIV and the combination of DNA vaccination plus recombinant vaccinia is one of the favored approaches in AIDS vaccine development.

该子项目是利用资源的众多研究子项目之一 由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持 并且子项目的主要研究者可能是由其他来源提供的， 包括其他 NIH 来源。 子项目可能列出的总成本 代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。 SIV DNA 疫苗和粘膜免疫 全球超过 80% 的 HIV 感染传播是通过粘膜途径发生的。 疫苗诱导粘膜免疫的能力可能是预防艾滋病毒感染和感染后出现的免疫缺陷综合症所必需的。 目前正在开发多种艾滋病候选疫苗，每种疫苗都有潜在的优点和缺点。 DNA 疫苗具有使其成为有吸引力的 HIV 候选疫苗的特性，并且 DNA 疫苗接种与重组痘苗的结合是艾滋病疫苗开发中最受欢迎的方法之一。